featured
Long-Term Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial
JAMA Oncol 2022 Sep 01;[EPub Ahead of Print], T Conroy, F Castan, A Lopez, A Turpin, M Ben Abdelghani, AC Wei, E Mitry, JJ Biagi, L Evesque, P Artru, T Lecomte, E Assenat, L Bauguion, M Ychou, O Bouché, L Monard, A Lambert, P HammelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.